Safety of drug-eluting stents

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue 6, 2008, Pages 316-328

  Windecker, Stephan ^a   Jüni, Peter ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; METAL; PACLITAXEL; PRASUGREL; RAPAMYCIN;

ACUTE CORONARY SYNDROME; ANGIOGRAPHY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; INCIDENCE; INTERMETHOD COMPARISON; LONG TERM CARE; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REOPERATION; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; THROMBOGENICITY; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION;

CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; PACLITAXEL; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 44449123786     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1189     Document Type: Review

References (69)

1. Morice MC et al.; RAVEL Study Group (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346: 1773-1780
2. Moses JW et al.; SIRIUS Investigators (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349: 1315-1323
3. Colombo A et al.; TAXUS II Study Group (2003) Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108: 788-794
4. Stone GW et al.; TAXUS-IV Investigators (2004) A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350: 221-231
5. Virmani R et al. (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circuladon 109: 701-705
6. Joner M et al. (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 193-202
7. Nebeker JR et al. (2006) Hypersensitivity cases associated with drug-eluting coronary stents: A review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47: 175-181
8. Finn AV et al. (2007) Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 115: 2435-2441
9. Pfisterer M et al.; BASKET-LATE Investigators (2006) Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48: 2584-2591
10. Daemon J et al. (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 369: 667-678
11. Babapulle MN et al. (2004) A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364: 583-591
12. Stone GW et al.; TAXUS V Investigators (2005) Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 294: 1215-1223
13. Serruys PW et al. (2006) Coronary-artery stents. N Engl J Med 354: 483-495
14. Stone GW et al. (2007) Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med 356: 998-1008
15. Stettler C et al. (2007) Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 370: 937-948
16. Tu JV et al. (2007) Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 357: 1393-1402
17. Lagerqvist B et al.; SCAAR Study Group (2007) Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356: 1009-1019
18. Jensen LO et al. (2007) Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 50: 463-470
19. Weaver WD et al. (2000) Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): A randomised trial. Lancet 355: 2199-2203
20. Walters DL et al. (2002) Acute coronary syndrome is a common clinical presentation of in-stent restenosis. Am J Cardiol 89 491-494
21. Chen MS et al. (2006) Bare metal stent restenosis is not a benign clinical entity. Am Heart J 151: 1260-1264
22. Doyle B et al. (2007) Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 116: 2391-2398
23. Stone GW et al. (2007) Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation 115: 2842-2847
24. Weintraub WS et al. (1993) Long-term clinical follow-up in patents with angiographic restudy after successful angioplasty. Circulation 67: 831-840
25. Van Belle E et al. (2001) Potency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: A key determinant of survival in diabetics after coronary balloon angioplasty. Circulation 103: 1218-1224
26. Schuhlen H et al. (2004) Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J 147: 317-322
27. Togni M et al. (2005) Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46: 231-236
28. Hofma SH et al. (2006) Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 27: 166-170
29. Togni M et al. (2007) Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol 120: 212-220
30. Mintz GS and Weissman NJ (2006) Intravascular ultrasound in the drug-eluting stent era. J Am Coll Cardiol 48: 421-429
31. Feres F et al. (2006) Very late thrombosis after drug-eluting stents. Catheter Cardiovasc Interv 68: 83-88
32. Cook S et al. (2007) Incomplete stent opposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 115: 2426-2434
33. Steffel J et al. (2005) Rapamycin, but not FK-506, increases endothelial tissue factor expression: Implications for drug-eluting stent design. Circulation 112: 2002-2011
34. Stahli BE et al. (2006) Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res 99:149-155
35. Cutlip DE et al. (2001) Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials. Circulation 103: 1967-1971
36. Mauri L et al. (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356: 1020-1029
37. Kuchulakanti PK et al. (2006) Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113: 1108-1113
38. Wenaweser P et al. (2005) Stent thrombosis following bare-metal stent implantation: Success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 26 1180-1187
39. Cutlip DE et al. on behalf of the Academic Research Consortium (2007) Clinical endpoints in coronary stent trials: A case for standardized definitions. Circulation 115: 2344-2351
40. Bavry AA et al. (2005) Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data). Am J Cardiol 95: 1469-1472
41. Bavry AA et al. (2005) What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: A meta-analysis. J Am Coll Cardiol 45 941-946
42. Calver AL et al. (2000) Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents. Am Heart J 140: 483-491
43. Heller LI et al. (2001) Late stent thrombosis in the absence of prior intracoronary brachytherapy. Catheter Cardiovasc Interv 53: 23-28
44. Wang F et al. (2002) Late coronary stent thrombosis: Early vs. late stent thrombosis in the stent era. Catheter Cardiovasc Interv 55: 142-147
45. Moreno R et al. (2005) Drug-eluting stent thrombosis: Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45: 954-959
46. Bavry AA et al. (2006) Late thrombosis of drug-eluting stents: A meta-analysis of randomized clinical trials. Am J Med 119: 1056-1061
47. Kastrati A et al. (2007) Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356: 1030-1039
48. James S et al. (online 2006) Drug eluting stents vs. bare metal stents in Sweden: The results of the SCAAR trial. [www.clinicaltrialresults.org] (accessed 14 February 2008)
49. Marzocchii A et al. (2007) Long-term safety and efficacy of drug-eluting stents: Two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Circulation 115: 3181-3188
50. Buring JE et al. (1995) Calcium channel blockers and myocardial infarction: A hypothesis formulated but not yet tested. JAMA 274: 654-655
51. Kaul S et al. (2007) As time goes by: Current status and future directions in the controversy over stenting. J Am Coll Cardiol 50: 128-137
52. Spaulding C et al. (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356: 989-997
53. Pache J et al. (2005) Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: A prospective, randomized trial. Eur Heart J 26: 1262-1268
54. Brunner-La Rocca HP et al.; BASKET Investigators (2007) Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 28: 719-725
55. Urban P et al.; e-Cypher Investigators (2006) Safety of coronary sirolimus-eluting stents in daily clinical practice: One-year follow-up of the e-Cypher registry. Circulation 113: 1434-1441
56. Sianos G et al. (2007) Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: The importance of thrombus burden. J Am Coll Cardiol 50: 573-583
57. Kastrati A et al. (2007) Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 28: 2706-2713
58. Wilson SH et al. (2003) Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 42: 234-240
59. Vicenzi MN et al. (2006) Coronary artery stenting and non-cardiac surgery - a prospective outcome study. Br J Anaesth 96: 686-693
60. Smith SC Jr et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention (2006) ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/AHA/ SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113: E166-286
61. Steinhubl SR et al.; CREDO Investigators (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial: Clopidogrel for the Reduction of Events During Observation. JAMA 288: 2411-2420
62. Mehta SR et al.; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percuteneous coronary intervention: The PCI-CURE study. Lancet 358: 527-533
63. Eisenstein EL et al. (2007) Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 207: 159-168
64. Airoldi F et al. (2007) Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116: 745-754
65. Wiviott SD et al.; TRITON-TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-2015
66. Grines CL et al.; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons American Dental Association; American College of Physicians (2007) Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115: 813-818
67. Hodgson J et al.; Society for Cardiovascular Angiography and Interventions (2007) Late stent thrombosis: Considerations and practical advice for the use of drug-eluting stents. Catheter Cardiovasc Intenv 69: 327-333
68. Iakovou I et al. (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293: 2126-2130
69. Ellis SG et al. (2007) Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: A TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol 49: 1043-1051